Compare Cyfuse Biomedical KK with Similar Stocks
Dashboard
1
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -84.91
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -84.91
2
Poor long term growth as Operating profit has grown by an annual rate -3.27% of over the last 5 years
3
Risky -
4
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 5,328 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.84
-30.03%
1.94
Revenue and Profits:
Net Sales:
76 Million
(Quarterly Results - Jun 2026)
Net Profit:
-210 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
33.2%
0%
33.2%
6 Months
11.29%
0%
11.29%
1 Year
16.75%
0%
16.75%
2 Years
16.16%
0%
16.16%
3 Years
-18.92%
0%
-18.92%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Cyfuse Biomedical KK for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
90.56%
EBIT Growth (5y)
-3.27%
EBIT to Interest (avg)
-70.85
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.84
Sales to Capital Employed (avg)
0.03
Tax Ratio
0.34%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.92
EV to EBIT
-3.72
EV to EBITDA
-3.89
EV to Capital Employed
6.63
EV to Sales
12.72
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-177.98%
ROE (Latest)
-30.03%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
75.80
5.20
1,357.69%
Operating Profit (PBDIT) excl Other Income
-195.40
-221.90
11.94%
Interest
5.80
2.60
123.08%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-210.40
-239.50
12.15%
Operating Profit Margin (Excl OI)
-2,657.80%
-44,346.60%
4,168.88%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is 1,357.69% vs -28.77% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is 12.15% vs -7.45% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
231.00
54.40
324.63%
Operating Profit (PBDIT) excl Other Income
-792.70
-860.10
7.84%
Interest
14.30
9.50
50.53%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-763.80
-872.20
12.43%
Operating Profit Margin (Excl OI)
-3,585.20%
-16,459.10%
1,287.39%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 324.63% vs -10.97% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 12.43% vs -48.03% in Dec 2024
About Cyfuse Biomedical KK 
Cyfuse Biomedical KK
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






